Kanina Crosen
Adult Health · Oxford, ALNPI 1346541273
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 31.4% of the total. Reporting peaked in 2022 at $1,163 and has fallen 70.9% since, to $338 in 2025.
Across 235 payments — averaging $14.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$697
- Otsuka America Pharmaceutical, Inc.$513
- Intra-sana Laboratories$226
- Bayer$146
- Biohaven Pharmaceutical Holding Company Ltd.$125
- plus $565 from 13 others
What the payments were for
- Food & beverage$3,11394%
- Gifts$2006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 101 | $1,041 |
| AbbVie | 53 | $697 |
| Otsuka America Pharmaceutical, Inc. | 28 | $513 |
| Intra-sana Laboratories | 2 | $226 |
| Bayer | 8 | $146 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $125 |
| Lilly USA, LLC | 5 | $92 |
| Currax Pharmaceuticals LLC | 6 | $86 |
| Pfizer | 3 | $63 |
| Ironwood Pharmaceuticals, Inc | 3 | $55 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Exact Sciences | 2 | $41 |
| Vivus LLC | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Amgen(2 entities) | 2 | $29 |
| Lundbeck LLC | 1 | $21 |
| Atland Pharmaceuticals, LLC | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$200
- Reltone 400 Mg$200
How this compares
$3,313 in reported general payments places this provider in the 80th percentile of 308 adult health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 19 | $211 |
Paid to pharmacies, not to this prescriber.
Other adult health in Oxford
- Wendy CantrellMountain Brk$276K
- Lanier OhareBirmingham$42K
- Jessica WrightBirmingham$33K
- Sara HopperBirmingham$21K
- Andrea SuttonBirmingham$21K
- Olivia ViseHoover$15K
- Lindsay SmithPelham$14K
- Alaina OdomAlabaster$14K
- Holly CluckMontgomery$12K
- Ashley YorkHoover$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.